Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on DexCom

Share:
Related DXCM
The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue
10 Biggest Price Target Changes For Friday

In a report published Friday, Jefferies & Company reiterated its Buy rating on DexCom (NASDAQ: DXCM), but lowered its price target from $18.00 to $16.50.

Jefferies noted, “DexCom released final 3Q revenues of $23.1mn after pre-announcing in early October with the G4 Platinum Sensor approval. The final 3Q numbers reflect a handful of one-time charges and adjustments; full year guidance was reiterated. The G4 and the subsequent pump combinations set the table for a good run.”

DexCom closed on Thursday at $13.07.

Latest Ratings for DXCM

DateFirmActionFromTo
Aug 2018Bank of AmericaMaintainsBuyBuy
Aug 2018BerenbergUpgradesHoldBuy
Aug 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (DXCM)

View Comments and Join the Discussion!

First You Have to Have a Job… Watch those Numbers $ES_F 1436 in Sight

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Life Technologies